Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 5/20 | 0.68 |
| ▸ | RNPEP | Q9H4A4 | 4/20 | 0.68 |
| ▸ | DNPEP | Q9ULA0 | 4/20 | 0.68 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.45 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RRM1 | P23921 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1277892 | 1.00 | ANPEP (0.68) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| SCHEMBL1277891 | 1.00 | ANPEP (0.68) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| Hydrochloric Acid SCHEMBL1277930 | 0.98 | ANPEP (0.66) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| Bromide SCHEMBL7305048 | 0.98 | ANPEP (0.66) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| SCHEMBL1769033 | 0.87 | SLC7A5 (0.59) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| SCHEMBL1769602 | 0.87 | SLC7A5 (0.59) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| SCHEMBL1768387 | 0.87 | SLC7A5 (0.59) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| SCHEMBL1769031 | 0.87 | SLC7A5 (0.59) | ANPEPRNPEPDNPEPSLC7A5DPP7 | |
| Bromide SCHEMBL7287179 | 0.86 | ANPEP (0.57) | ANPEPRNPEPDNPEPSLC7A5LAP3 | |
| SCHEMBL9113004 | 0.86 | DPP7 (0.52) | ANPEPRNPEPDNPEPSLC7A5DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227806-A1 | Novel Drugs for Dementia | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227806-A1 | Novel Drugs for Dementia | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2008-09-18 | — | — | US | disclosed |
| WO-2007038772-A1 | NOVEL DRUGS FOR DEMENTIA | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227806-A1 | Novel Drugs for Dementia | CTSS, PRSS1, CBS | ANPEP 89/4885RNPEP 209/4885DNPEP 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.